FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to molecular biology and medicine, in particular to novel antibody molecules that specifically bind to TNFR2 on a target cell and are thereby agonists to TNFR2, but do not block the TNF-α ligand from binding with TNFR2. Also described is the use of such antibody molecules in medicine, for example, in the treatment of cancer or chronic inflammatory diseases.
EFFECT: disclosed antibodies are powerful therapeutic agents and are useful in medicine.
37 cl, 22 dwg, 10 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PRE-S1 HBV ANTIBODIES | 2016 |
|
RU2739955C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
| PARTICLES CONJUGATED TO PEPTIDE | 2014 |
|
RU2813163C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| CD3-SPECIFIC BINDING MOLECULES | 2020 |
|
RU2826453C2 |
| COMPOSITIONS AND METHODS OF PRODUCING T-CELL COMPOSITIONS AND USE THEREOF | 2020 |
|
RU2835034C2 |
| METHOD FOR PREVENTION AND TREATMENT OF CANCER METASTASES AND BONE LOSS CAUSED BY CANCER METASTASES | 2007 |
|
RU2470665C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
| POLYPEPTIDE LINKER FOR PRODUCTION OF MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2776302C2 |
